CTIS2023-507171-22-00招募中1 期
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation - BO44426
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy, No prior systemic treatment for advanced unresectable or metastatic NSCLC, Confirmation of Biomarker eligibility: – Valid results from either central testing of tissue or local testing of blood or tissue documenting the presence of the KRAS G12C mutation – Valid results from either central or local testing of tissue documenting expression of PD-L1. For Cohort A, PD-L1 tumor cell expression >= 1% is required to be eligible. Patients in Sweden are required to have documented history of PD-L1 tumor cell expression =50%. For Cohort B, PD-L1 tumor cell expression is not required to be eligible. Local testing of tumor tissue for PD-L1 expression must be performed at an appropriately accredited/certified laboratory, Pretreatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin-embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor., Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
排除标准
- •Known concomitant second oncogenic driver with available targeted treatment, Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases, Prior treatment with a KRAS G12C inhibitor, Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only), History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer, Uncontrolled tumor-related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia, History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or intravenously (IV) plus Lenalidomide (+Len) in Patients with Follicular LymphomaCTIS2023-507236-20-00F. Hoffmann-La Roche AG187
进行中（未招募）
1 期
Safety and tolerability of MEDI4736 in Combination With AZD9150 or AZD5069 in solid tumors and subsequently evaluating AZD9150 or AZD5069 as single agent or in combinations with MEDI4736 in Patients with recurrance or spread of Squamous Cell Carcinoma of the Head and NeckEUCTR2015-002525-19-ESAstraZeneca AB184
进行中（未招募）
1 期
Safety and tolerability of MEDI4736 in Combination With AZD9150 or AZD5069 in solid tumors and subsequently evaluating AZD9150 or AZD5069 as single agent or in combinations with MEDI4736 in Patients with recurrance or spread of Squamous Cell Carcinoma of the Head and NeckEUCTR2015-002525-19-DEAstraZeneca AB335
进行中（未招募）
1 期
Safety and tolerability of MEDI4736 in Combination With AZD9150 or AZD5069 in solid tumors and subsequently evaluating AZD9150 or AZD5069 as single agent or in combinations with MEDI4736 in Patients with recurrance or spread of Squamous Cell Carcinoma of the Head and NeckPart A (US ONLY): advanced solid malignancies Part B (NA, EU): Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 20.0Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002525-19-BEAstraZeneca AB335
进行中（未招募）
1 期
Safety and tolerability of MEDI4736 in Combination With AZD9150 orAZD5069 in solid tumors and subsequently evaluating AZD9150 orAZD5069 as single agent or in combinations with MEDI4736 in Patientswith recurrance or spread of Squamous Cell Carcinoma of the Head andNeckEUCTR2015-002525-19-ITASTRAZENECA AB335